Literature DB >> 30008863

Expression of ZEBs in gliomas is associated with invasive properties and histopathological grade.

Keiko Suzuki1, Tomoyuki Kawataki1, Kaori Endo2, Keiji Miyazawa2, Hiroyuki Kinouchi1, Masao Saitoh2,3.   

Abstract

The invasiveness of glioma cells is the predominant clinical problem associated with this tumor type, and is correlated with pathological malignant grade. ZEB1 is highly expressed in glioma cells and associated with the aggressiveness of various types of cancer. In the present study, the expression of ZEB1 and ZEB2 was examined with the aim of determining the role of ZEBs in glioma. ZEB1 and ZEB2 were highly expressed in all glioma cells used in this study. Double knockdown of ZEB1 and ZEB2 suppressed tumor invasiveness more effectively than knockdown of either alone, in both in vitro and in vivo experiments. ZEB1 and ZEB2 were marginally expressed in grade II, but expressed at higher levels in grade IV. Importantly, ZEB-positive cells were more abundant in recurrent glioma with malignant transformation than in initial grade II tissue from the same case. These results indicate that the levels of ZEB1 and ZEB2 are positively correlated with histopathological grade and invasiveness of glioma, suggesting that δEF1 family proteins (ZEB1 and ZEB2) could be useful as prognostic markers and therapeutic targets in patients with glioma.

Entities:  

Keywords:  ZEB1 (δEF1); ZEB2 (SIP1); gene silencing; glioma; invasion

Year:  2018        PMID: 30008863      PMCID: PMC6036434          DOI: 10.3892/ol.2018.8852

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  18 in total

Review 1.  Malignant gliomas in adults.

Authors:  Patrick Y Wen; Santosh Kesari
Journal:  N Engl J Med       Date:  2008-07-31       Impact factor: 91.245

Review 2.  EMT: 2016.

Authors:  M Angela Nieto; Ruby Yun-Ju Huang; Rebecca A Jackson; Jean Paul Thiery
Journal:  Cell       Date:  2016-06-30       Impact factor: 41.582

3.  Identification of integrin α3 as a molecular marker of cells undergoing epithelial-mesenchymal transition and of cancer cells with aggressive phenotypes.

Authors:  Takuya Shirakihara; Tomonori Kawasaki; Akihiko Fukagawa; Kentaro Semba; Ryuichi Sakai; Kohei Miyazono; Keiji Miyazawa; Masao Saitoh
Journal:  Cancer Sci       Date:  2013-07-20       Impact factor: 6.716

4.  TGF-β drives epithelial-mesenchymal transition through δEF1-mediated downregulation of ESRP.

Authors:  K Horiguchi; K Sakamoto; D Koinuma; K Semba; A Inoue; S Inoue; H Fujii; A Yamaguchi; K Miyazawa; K Miyazono; M Saitoh
Journal:  Oncogene       Date:  2011-10-31       Impact factor: 9.867

5.  δEF1 associates with DNMT1 and maintains DNA methylation of the E-cadherin promoter in breast cancer cells.

Authors:  Akihiko Fukagawa; Hiroki Ishii; Keiji Miyazawa; Masao Saitoh
Journal:  Cancer Med       Date:  2014-10-15       Impact factor: 4.452

Review 6.  The Regulatory Role of MicroRNAs in EMT and Cancer.

Authors:  Apostolos Zaravinos
Journal:  J Oncol       Date:  2015-03-25       Impact factor: 4.375

7.  Ets1 and ESE1 reciprocally regulate expression of ZEB1/ZEB2, dependent on ERK1/2 activity, in breast cancer cells.

Authors:  Nguyen Duy Sinh; Kaori Endo; Keiji Miyazawa; Masao Saitoh
Journal:  Cancer Sci       Date:  2017-05-22       Impact factor: 6.716

Review 8.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

9.  Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer.

Authors:  Xiaofeng Zheng; Julienne L Carstens; Jiha Kim; Matthew Scheible; Judith Kaye; Hikaru Sugimoto; Chia-Chin Wu; Valerie S LeBleu; Raghu Kalluri
Journal:  Nature       Date:  2015-11-11       Impact factor: 49.962

10.  Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance.

Authors:  Kari R Fischer; Anna Durrans; Sharrell Lee; Jianting Sheng; Fuhai Li; Stephen T C Wong; Hyejin Choi; Tina El Rayes; Seongho Ryu; Juliane Troeger; Robert F Schwabe; Linda T Vahdat; Nasser K Altorki; Vivek Mittal; Dingcheng Gao
Journal:  Nature       Date:  2015-11-11       Impact factor: 49.962

View more
  6 in total

1.  Far-Red Fluorescent Murine Glioma Model for Accurate Assessment of Brain Tumor Progression.

Authors:  Tatiana A Mishchenko; Irina V Balalaeva; Maria O Klimenko; Anna A Brilkina; Nina N Peskova; Evgenii L Guryev; Dmitri V Krysko; Maria V Vedunova
Journal:  Cancers (Basel)       Date:  2022-08-06       Impact factor: 6.575

2.  ZNF276 promotes the malignant phenotype of breast carcinoma by activating the CYP1B1-mediated Wnt/β-catenin pathway.

Authors:  Ting Lei; Wenwu Zhang; Yongyin He; Shi Wei; Xiaoyu Song; Yi Zhu; Guoqing Luo; Zhenzhan Kuang; Guanjie Li; Quan Zhou; Zhaohui Sun; Bin Xiao; Linhai Li
Journal:  Cell Death Dis       Date:  2022-09-10       Impact factor: 9.685

3.  miR-637 Prevents Glioblastoma Progression by Interrupting ZEB2/WNT/β-catenin Cascades.

Authors:  Wei Wang; Zilong Zhao; Shuai Han; Di Wu
Journal:  Cell Mol Neurobiol       Date:  2021-05-28       Impact factor: 4.231

Review 4.  Divide et Impera: Drp1-mediated Mitochondrial Fission in Glioma Malignancy.

Authors:  Dianelena Eugenio-Pérez; Alfredo Briones-Herrera; Elena Martínez-Klimova; José Pedraza-Chaverri
Journal:  Yale J Biol Med       Date:  2019-09-20

5.  MicroRNA-769-3p inhibits tumor progression in glioma by suppressing ZEB2 and inhibiting the Wnt/β-catenin signaling pathway.

Authors:  Kai Wang; Shasha Yang; Yishen Gao; Caihong Zhang; Qiangbo Sui
Journal:  Oncol Lett       Date:  2019-11-21       Impact factor: 2.967

6.  Carbonic Anhydrase XII is a Clinically Significant, Molecular Tumor-Subtype Specific Therapeutic Target in Glioma with the Potential to Combat Invasion of Brain Tumor Cells.

Authors:  Guanzhang Li; Ting-Wei Chen; Ann-Christin Nickel; Sajjad Muhammad; Hans-Jakob Steiger; Theophilos Tzaridis; Daniel Hänggi; Reinhard Zeidler; Wei Zhang; Ulf Dietrich Kahlert
Journal:  Onco Targets Ther       Date:  2021-03-04       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.